Studying fluid around the lungs in lung cancer patients to aid diagnosis
Follows adults with lung cancer and fluid around the lungs to predict outcomes.
Plain-language title generated from the registry record
Registry title: Union-LC-MPE Cohort:A Multicenter Cohort Study on Diagnosis and Prognosis of Malignant Pleural Effusion in Lung Cance
Key facts
- Where
- Wuhan, ChinaSee the site
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The study is looking for adults with malignant pleural effusion (fluid around the lung caused by cancer) that comes from lung cancer.
- Age
- 18 years or older
- Sex
- Any sex can join
- Disease stage
- Malignant pleural effusion that comes from lung cancer. It is confirmed by fluid cytology, pleural biopsy, or a clinical and imaging assessment.
Main reasons for not taking part
- Pleural effusion caused by cancer that spread to the lung from another site
- Another primary malignant tumor at the same time
- Severe lack of key clinical, imaging, or laboratory data
- Death within 30 days after the effusion was diagnosed
- Mental disorder that prevents taking part in follow-up
Read by machine on 9 November 2026.
Where in China
- Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyWuhan, ChinaNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
- Trial code
- NCT07882758
- Record updated
- 27 October 2026
- Original description
Lung cancer is the malignant tumor with the highest incidence and mortality rates in China. Malignant pleural effusion (MPE) is one of its most common complications, affecting approximately 15%-50% of patients with non-small cell lung cancer at initial diagnosis or during disease progression and indicating advanced-stage disease with a median survival of only 3-12 months. This study aims to establish the first large-scale, multicenter LC-MPE disease-specific cohort, integrating clinical, imaging, pleural fluid laboratory, pathological and genomic multimodal data to develop an AI-assisted model for the differential diagnosis of benign versus malignant MPE and a prognostic prediction model for LC-MPE patients. The study comprises a retrospective phase (3,000 patients diagnosed between January 2022 and September 2026) and a prospective phase (200 patients diagnosed between October 2026 and October 2028). The primary endpoint is overall survival (OS); secondary endpoints include pleural effusion progression-free survival (PE-PFS), duration of pleural effusion control, and 60-day and 30-day MPE recurrence rates. This observational study does not interfere with routine clinical care and strictly protects the personal information of participants.Read full original descriptionShow less
Union-LC-MPE Cohort:A Multicenter Cohort Study on the Diagnosis and Prognosis of Malignant Pleural Effusion in Lung Cancer Based on Integrated Clinical, Radiological, and Pleural Fluid Multi-Omics Data
Lung cancer is the malignant tumor with the highest incidence and mortality rates in China. Malignant pleural effusion (MPE) is one of its most common complications, affecting approximately 15%-50% of patients with non-small cell lung cancer at initial diagnosis or during disease progression and indicating advanced-stage disease with a median survival of only 3-12 months. This study aims to establish the first large-scale, multicenter LC-MPE disease-specific cohort, integrating clinical, imaging, pleural fluid laboratory, pathological and genomic multimodal data to develop an AI-assisted model for the differential diagnosis of benign versus malignant MPE and a prognostic prediction model for LC-MPE patients. The study comprises a retrospective phase (3,000 patients diagnosed between January 2022 and September 2026) and a prospective phase (200 patients diagnosed between October 2026 and October 2028). The primary endpoint is overall survival (OS); secondary endpoints include pleural effusion progression-free survival (PE-PFS), duration of pleural effusion control, and 60-day and 30-day MPE recurrence rates. This observational study does not interfere with routine clinical care and strictly protects the personal information of participants.
Inclusion: Age 18 years or older; gender not restricted; Malignant pleural effusion of lung cancer origin; Diagnosis confirmed by positive pleural fluid cytology, pleural biopsy, or clinical/imaging comprehensive assessment.
Exclusion: Concurrent presence of other primary malignant tumors; Pleural effusion caused by secondary lung cancer (metastasis to the lung from tumors at other sites); Death within 30 days after diagnosis of malignant pleural effusion; Mental disorders that prevent cooperation with follow-up; Severe lack of critical clinical, imaging, or laboratory data.